J. Matthews

发表

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

S. Jagannath, C. Cordon-Cardo, V. Simon, 2021, Cancer Cell.

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

V. Simon, L. Mulder, F. Krammer, 2021, The New England journal of medicine.

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

A. García-Sastre, V. Simon, L. Mulder, 2021, The Lancet Microbe.

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

H. van Bakel, Julian Q. Zhou, V. Simon, 2021, Cell.

Duration of viable virus shedding in SARS-CoV-2 omicron variant infection

Ashutosh Kumar Singh, Y. Li, M. Siedner, 2022, medRxiv.

Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37

H. van Bakel, D. Sather, V. Simon, 2021, medRxiv.

Kinetics and durability of humoral responses to SARS-CoV-2 infection and vaccination

M. Sullivan, A. Nardulli, V. Simon, 2023, medRxiv.

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing 1 antibodies and targets both the NTD and the RBD 2

F. Krammer, G. Bajic, A. Ellebedy, 2021 .